🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 9 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 27/10/1993 | 7,63 | 7,63 | 7,38 | 7,50 | -1,64% | 3,28% | 16.200 |
| 26/10/1993 | 7,63 | 7,63 | 7,38 | 7,63 | +5,17% | 3,28% | 20.000 |
| 25/10/1993 | 7,50 | 7,63 | 7,25 | 7,25 | -1,69% | 5,00% | 34.000 |
| 22/10/1993 | 7,25 | 7,50 | 7,25 | 7,38 | +0,00% | 3,45% | 44.800 |
| 21/10/1993 | 7,63 | 7,63 | 7,25 | 7,38 | -1,67% | 4,92% | 29.000 |
| 20/10/1993 | 8,00 | 8,38 | 7,25 | 7,50 | -6,25% | 14,06% | 195.800 |
| 19/10/1993 | 8,25 | 8,50 | 8,00 | 8,00 | -5,88% | 6,06% | 110.000 |
| 18/10/1993 | 9,00 | 9,00 | 8,25 | 8,50 | -5,56% | 8,33% | 281.200 |
| 15/10/1993 | 9,13 | 9,50 | 8,75 | 9,00 | -4,00% | 8,22% | 400.600 |
| 14/10/1993 | 8,13 | 9,38 | 8,00 | 9,38 | +21,95% | 16,92% | 740.800 |
| 13/10/1993 | 7,63 | 7,88 | 7,38 | 7,69 | +0,82% | 6,56% | 225.000 |
| 12/10/1993 | 7,38 | 7,63 | 7,13 | 7,63 | +10,91% | 6,78% | 413.600 |
| 11/10/1993 | 6,50 | 7,13 | 6,25 | 6,88 | +5,77% | 13,46% | 277.000 |
| 08/10/1993 | 6,50 | 6,50 | 6,25 | 6,50 | +1,96% | 3,85% | 209.200 |
| 07/10/1993 | 6,38 | 6,38 | 6,13 | 6,38 | +0,00% | 3,92% | 97.800 |
| 06/10/1993 | 6,25 | 6,38 | 6,13 | 6,38 | +2,00% | 4,00% | 184.600 |
| 05/10/1993 | 6,38 | 6,38 | 6,13 | 6,25 | -1,96% | 3,92% | 52.000 |
| 04/10/1993 | 6,25 | 6,38 | 6,00 | 6,38 | +2,00% | 6,00% | 210.200 |
| 01/10/1993 | 6,13 | 6,38 | 6,00 | 6,25 | -1,96% | 6,12% | 137.600 |
| 30/09/1993 | 6,50 | 6,50 | 6,13 | 6,38 | -1,92% | 5,77% | 194.400 |
| 29/09/1993 | 6,38 | 6,63 | 6,13 | 6,50 | +15,56% | 7,84% | 388.800 |
| 28/09/1993 | 5,56 | 5,75 | 5,50 | 5,63 | +2,27% | 4,49% | 50.200 |
| 27/09/1993 | 5,50 | 5,75 | 5,50 | 5,50 | -1,12% | 4,55% | 13.200 |
| 24/09/1993 | 5,50 | 5,75 | 5,50 | 5,56 | -3,26% | 4,55% | 11.600 |
| 23/09/1993 | 5,50 | 5,75 | 5,50 | 5,75 | +4,55% | 4,55% | 61.400 |
| 22/09/1993 | 5,50 | 5,75 | 5,50 | 5,50 | -1,12% | 4,55% | 41.200 |
| 21/09/1993 | 5,38 | 5,75 | 5,38 | 5,56 | +1,14% | 6,98% | 56.200 |
| 20/09/1993 | 5,25 | 5,50 | 5,25 | 5,50 | +2,33% | 4,76% | 34.800 |
| 17/09/1993 | 5,50 | 5,50 | 5,25 | 5,38 | +0,00% | 4,55% | 60.400 |
| 16/09/1993 | 5,38 | 5,50 | 5,25 | 5,38 | +0,00% | 4,65% | 78.000 |